Lincoln Pharmaceuticals Limited Q3 FY26 earnings call summary

Earnings call of 18 Feb 2026, summarised by AI from the filing.

Canada business $4-5 mn this year, 6 Health Canada lines approved.

Key takeaways

1. Driver Canada business $4-5 mn this year, 6 Health Canada lines approved.
2. Risk Currency fluctuations and geopolitical situation cause quarter-to-quarter variations.

Original filing on BSE

Lincoln Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹177 cr (+15% year on year), EBITDA ₹27.4 cr (+19% year on year), PAT ₹36.2 cr (+29% year on year), EBITDA margin 15.5% (+54 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹187 cr (+11% year on year), EBITDA ₹24.9 cr (−4% year on year), PAT ₹11.6 cr (−3% year on year), EBITDA margin 13.3% (−221 bps). Score 45 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was below it. EBITDA margin fell 221 bps year on year. Profit fell 59% from last quarter. Share price after the results: −16.7% in 28 days (Nifty 500: +0.6%).
• Q3 FY26: Revenue ₹166 cr (+13% year on year), EBITDA ₹23.6 cr (−2% year on year), PAT ₹28.6 cr (+36% year on year), EBITDA margin 14.2% (−214 bps). Score 47 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was well above it. EBITDA margin fell 214 bps year on year. Other income 44% of PBT. Share price after the results: +14.1% in 29 days (Nifty 500: −10.1%).
• Q2 FY26: Revenue ₹163 cr (+1% year on year), EBITDA ₹26.0 cr (−7% year on year), PAT ₹20.0 cr (−23% year on year), EBITDA margin 16.0% (−144 bps). Score 31 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 144 bps year on year. Profit fell 29% from last quarter. Share price after the results: −10.7% in 29 days (Nifty 500: −0.5%).
• Q1 FY26: Revenue ₹154 cr (+5% year on year), EBITDA ₹23.0 cr (+5% year on year), PAT ₹28.0 cr (+17% year on year), EBITDA margin 14.9% (−3 bps). Score 39 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin was flat year on year. Other income 43% of PBT. Revenue fell 8% from last quarter. Share price after the results: +5.2% in 29 days (Nifty 500: +0.7%).
• Q4 FY25: Revenue ₹168 cr (+18% year on year), EBITDA ₹26.0 cr (+37% year on year), PAT ₹12.0 cr (−37% year on year), EBITDA margin 15.5% (+210 bps). Score 64 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was well below it. EBITDA margin rose 210 bps year on year. Profit fell 43% from last quarter. Share price after the results: −7.3% in 29 days (Nifty 500: +1.4%).
• Q3 FY25: Revenue ₹147 cr (+1% year on year), EBITDA ₹24.0 cr (−20% year on year), PAT ₹21.0 cr (−25% year on year), EBITDA margin 16.3% (−422 bps). Score 7 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 422 bps year on year. Other income 31% of PBT. Revenue fell 9% from last quarter.
• Q2 FY25: Revenue ₹161 cr (+3% year on year), EBITDA ₹28.0 cr (−10% year on year), PAT ₹26.0 cr (−7% year on year), EBITDA margin 17.4% (−248 bps). Score 17 of 100, Below trend. EBITDA margin fell 248 bps year on year. Other income 29% of PBT. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Lincoln Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q3 FY26: Earnings call (18 Feb 2026)